Sign in
Join
Discovery/Preclinical
In vitro
In vivo
Newer Targets
Clinical
Approval
FDA/EMA/Drug Designation
IND
Launch
NDA
Phase I
Phase II
Phase III
Recall
Commercial
Acquisitions
Conference/Award
Deals
Financial
Lawsuits/Bankruptcy
Lay off/Spin-off/Appointments
Merger
Patent
Pricing
Sign in
Welcome!
Log into your account
your username
your password
Forgot your password?
Sign up
Welcome!
Register for an account
your email
your username
A password will be e-mailed to you.
Password recovery
Recover your password
your email
Search
Sign in / Join
Contact
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Create an account
Create an account
Welcome! Register for an account
your email
your username
A password will be e-mailed to you.
Password recovery
Recover your password
your email
A password will be e-mailed to you.
Discovery/Preclinical
All
In vitro
In vivo
Newer Targets
In vivo
EIP Pharma Announces Presentation of Preclinical Data Demonstrating Effects of p38?…
Newer Targets
Targeting a key protein may keep ovarian cancer cells from spreading
Newer Targets
Marathon-running molecule could speed up the race for new neurological treatments
Newer Targets
Targeting a key protein may keep ovarian cancer cells from spreading
Clinical
All
Approval
FDA/EMA/Drug Designation
IND
Launch
NDA
Phase I
Phase II
Phase III
Recall
Phase II
Ascendis Pharma Announces Filing of Investigational New Drug (IND) Application for…
Approval
Blueprint Medicines Announces European Medicines Agency Validation of Marketing Authorization Application…
Phase I
Cotinga Pharmaceuticals Releases Additional Interim Data of Phase 1b/2a Combination Trial…
Phase II
InflaRx Reports Additional Analysis of the SHINE Phase IIb Results for…
Commercial
All
Acquisitions
Conference/Award
Deals
Financial
Lawsuits/Bankruptcy
Lay off/Spin-off/Appointments
Merger
Patent
Pricing
Deals
Mallinckrodt And Silence Therapeutics Announce Collaboration To Develop And Commercialize RNAi…
Deals
Mallinckrodt To Make An Equity Investment In Silence Therapeutics As Part…
Commercial
Novartis Close to Settling Kickback Lawsuit
Deals
Predictive Oncology Subsidiary Helomics Collaborates with UPMC to Establish a Data…
Home
Commercial
Lay off/Spin-off/Appointments
Lay off/Spin-off/Appointments
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
Lay off/Spin-off/Appointments
Aurinia Announces Further Strengthening of the Senior Management Team
Biospace News
-
July 18, 2019
Lay off/Spin-off/Appointments
Gilead CSO, Other Executives, Departing Company as CEO Continues to Reshape C-Suite
Lay off/Spin-off/Appointments
Inovio, Amneal Slash Workforces as Both Companies Undergo Realignments
Lay off/Spin-off/Appointments
Checkmate Pharmaceuticals Announces Appointment of Alan Fuhrman to Board of Directors
Lay off/Spin-off/Appointments
Immunic, Inc. Appoints Sanjay S. Patel, CFA, as Chief Financial Officer
Lay off/Spin-off/Appointments
Akebia Therapeutics CEO, John P. Butler, Elected Chair of Kidney Care...
Biospace News
-
July 11, 2019
0
Lay off/Spin-off/Appointments
Ampio Appoints Moss Adams LLP as the Company’s New Independent Auditor
Biospace News
-
July 11, 2019
0
Lay off/Spin-off/Appointments
Akebia Therapeutics CEO, John P. Butler, Elected Chair of Kidney Care...
Biospace News
-
July 11, 2019
0
Lay off/Spin-off/Appointments
Ampio Appoints Moss Adams LLP as the Company’s New Independent Auditor
Biospace News
-
July 11, 2019
0
Lay off/Spin-off/Appointments
Amneal Pharmaceuticals Announces Restructuring and Costs Savings Plan to Improve Operations...
Biospace News
-
July 10, 2019
0
1
2
3
...
26
Page 1 of 26
- Advertisement -
MOST POPULAR
BioSpace Global Roundup, May 23
May 23, 2019
Senate Finance Committee and House Oversight Committee Take Aim at Drug...
January 30, 2019
Cutting-Edge Discovery Points to Potential Treatment for Necrotizing Enterocolitis in Preemies
April 23, 2019
Portola’s Ondexxya conditionally cleared in Europe as antidote for reversal of...
April 26, 2019
Load more
HOT NEWS
Commercial
Alkermes Plc Reports Financial Results for the Year Ended Dec. 31,...
NDA
DBV Technologies to re-file Viaskin Peanut allergy treatment in US later...
Others
Taro Provides Results for the Year Ended March 31, 2019
Clinical
Zogenix Ready to Resubmit Fintepla for Rare Epilepsy to FDA
